tereotactic radiosurgery is used for highly focused radiation treatment of relatively small intracranial targets. Extracranial treatment systems are currently in development and used at a few centers. Approaches are image-based or image-guided, using CT andlor MR anatomical imaging. Biological imaging may provide non-invasive detection of the biological character and spatial extent of intracranial and extracranial targets. Potential uses of biological imaging in stereotactic radiosurgery include target delineation and normal tissue identification. These aspects are reviewed to explore the potential uses and impact these images may have on radiosurgery treatment.
Introduction
Stereotactic radiosurgery can be accomplished using linear accelerator devices and gamma units in single fraction or multi-fraction, static or dynamic, and framebased or frameless approaches (I, 2). The procedure is accomplished using imagebased targeting based on projection images (ie, plane radiographs), computerized tomography (CT) images, and/or magnetic resonance (MR) images. A rigid headframe or other fixation device is applied to the patient that establishes a reference coordinate system and is used for treatment immobilization and positioning. During imaging a device containing fiducial markings (usually "N" or "Z" shaped lines or a series of identifiable dots or markings, of materials that are specific to the imaging modality being used) is added to or integrated in the patient fixation device. These marks appear in the patient images and provide known points of reference for coordinate system determination, relative to the patient fixation device. The stable or accurately repositioned fixation device maintains the coordinate sYStem and allows i) image-based identification of a target and its coordinates and ii) delivery of the radiation treatment through accurate positioning of the intracranial target at the treatment isocenter or focus (1-3). While originally based on films acquired at the time of imaging, stereotactic coordinate systems are now computed automatically from digital images that are transferred directly from the imaging device to the radiosurgery treatment planning system. MR, for high soft tissue contrast, and CT, for geometric fidelity, are by far the most commonly used imaging modalities. Projection images in bi-planar imaging are used for angiographic cases. These imaging modalities produce patient images that contain patient anatomy and reference marks for the coordinate system. Anatomical imaging of an intracranial target with MR and CT may show an enhancing region of a tumor, with natural or added contrast. While some com pro-mised function of the blood-brain barrier may be imageable, in general these imaging modalities show anatomy, and do not show the metabolic or biologic character of a tumor. Certain biological characteristics of tumor may be important determinants in radiation response. For instance, cell hypoxia may indicate regions refractory to radiation treatment, and proliferation may indicate regions of active tumor growth. Thus, in vivo biological imaging, also called molecular or functional imaging (as in physiological function), of tumor characteristics is of high interest to the oncology community (4, 5) . Biological imaging has potential to change the practice of radiation treatment by advancing diagnosis, enabling biologically-directed radiation treatment, and aiding treatment evaluation (6, 7) . Types of biological images are now reviewed with their possible applications in the radiosurgical setting.
Biological Image Modalities
Definitions of biological or molecular imaging vary, depending on the task or application. In general, biological or molecular imaging is the field whereby tissues or cells of a particular state, or other species (proteins, molecules), can be imaged or used to image biological or molecular structure, function, or processes. The resolution scale of molecular imaging procedures covers approximately 4 orders of magnitude, from the use of fluorescent proteins at the sub-cellular level (I lim resolution) up to positron emission tomography/nuclear medicine imaging (I em resolution) (8) . Three general modalities are being used to produce images: i) radioisotopes, ii) magnetic resonance, and iii) optical approaches.
Radioisotope methods include tracer approaches and nuclear medicine imaging using single photon emission computed tomography (SPECT) and positron emission tomography (PET). These techniques require the delivery of a radioisotope to the area to be imaged. The radioisotope may be attached to a specific molecule that selectively determines the binding location of the tagged material (9) (for instance, radiolabled antibodies with specific binding activity to a tumor that are imaged using SPECT). Magnetic resonance imaging (MRI) can be accomplished over a range from very fine to fine resolution (lim to mm to em), and includes spectroscopy, diffusion, perfusion, hypoxia mapping, and functional imaging approaches (10, 11) . With MRI, both "anatomical" imaging (T'l-weighted and T2-weighted) and biological or molecular imaging can be performed. Magnetic resonance spectroscopic imaging (MRSI), also referred to as Chemical Shift Imaging (CSI), in particular holds promise for oncologic imaging by producing images of metabolite concentrations contained within a voxeI. The presence of certain metabolites may indicate the presence of tumor cells within the voxeI. Optical biomolecularimaging uses optical and infrared photons for imaging, usually at very high resolution (12) . Optical techniques include bioluminescence and optical coherent tomography, for example. Molecular imaging remains a developing field and is being encouraged through National Cancer Institute initiatives (5), including establishment of five national In Vivo Cellular and Molecular Imaging Centers and fourteen planning grants for additional centers (13, 14) .
Biological Imaging in Ncuro-Oncology
Neuro-oncology imaging is challenged by the detection of low soft tissue contrast that indicates presence of a tumor. MR imaging has provided dramatic changes in the imaging capabilities of gliomas since MRI's soft tissue contrast, with and without contrast agents, is so superior to that of CT. Thus, MRI is the imaging modality of choice for neurooncologic diagnosis and treatment planning. Besides "anatomical" imaging by pulse sequences that show magnetic moment maps of enhanced or non-enhanced objects, for instance, acquired through TI-weighted, T2-weighted or volume scanning, MRS I can be performed to determine the metabolite composition of a voxel. MRSI was developed from MR spectroscopy (non-imaging) and uses the spectral peak location (frequency) to identify the metabolite and the peak height or ratio of peak heights to determine voxel intensity. MRSI started as single voxel measurements, however, multi-voxel capabilities now exist. MRS I has been used in prostate and glioma imaging (15) to determine radiation target volumes from maps of anaerobic metabolites. Nelson et al. have developed a technique for determining voxel intensity based on the ratios of the metabolite peaks (16) . Pathology and imaging datasets were compared to derive the peak ratio threshold that indicates positive tumor. A specialized software toolset is required for programming the MR scan sequence parameters and for reconstructing the images. Vendors are beginning to provide commercial products with their MR scanners, however, spectroscopic imaging remains a widely investigated field. In particular, increasing the MR unit field strength (ie, from 1.5 T to 3.0 T) allows greater separation of the metabolite peaks, enabling better resolution for metabolite identification.
MRSI has been investigated by Pirzkall et al. at the University of California San Francisco (UCSF) for external beam radiation therapy treatment planning of both low-and high-grade gliomas. In 20 patients with infiltrative lowgrade astrocytomas, the MRSI tumor volume was compared to the T2-weighted MRI tumor volume (17) . Multi-voxel MRSI was performed. A choline to N-acetyl-aspartate ratio or index (eNI) of >2: I was considered positive for tumor in a given voxeI. The MRS I volume was larger than the T2-weighted MRI volume in a non-uniform way in 9 of 20 (45%) patients. The median volume increase was 2.3cc (range, I. 4-5.2cc patients with anaplastic astrocytoma (AA) and 12 with glioblastoma multiforme (GBM) was performed by the UCSF group (18) . T2-weighted MRI was found to both over-and under-estimate the volume of microscopic disease compared to MRSI in 60-95% of patients. In other words, the edema volume seen on T2-weighted MRI, traditionally thought to represent the anatomic extent of microscopic disease in malignant glioma (19) , has areas of normal brain tissue within it (hence, an over-estimate) as well as areas of tumor that extend beyond it (hence, an under-estimate). T 1-weighted MRI with contrast underestimated the volume of gross disease compared to MRSI by an average of 38mm (range, 31-50mm) in anaplastic astrocytoma, and by 24mm on average (range, 16-28mm) in GBM. In a more recent study, the UCSF group performed postoperative/pre-radiation Tl-and T2-weighted MRI and MRSI in 30 patients with either GBM (27 patients) or AA (3 patients) (20) . In 27 of 30 patients (90%), MRSI demonstrated a larger volume of residual disease than the TI-weighted MRI by a mean volume of 20-21 cc and a diameter ranging from 8-36mm. Furthermore, the T2-weighted MRI underestimated the volume of microscopic disease in 19 of 30 patients (63%) by a mean volume of7-8cc and a diameter ranging from 8-23mm. The MRS I volume was up to 86-180% larger than the T2-weighted MRI volume (average, 13-14% larger).
Both Positron Emission Tomography (PET) and IMT-SPECT (lodine-123-alpha methyltyrosine Single Photon Emission Computed Tomography) have also been used for radiation therapy treatment planning in conjunction with CT and MRI scans for brain tumors (21-23). In III patients with gliomas, Grosu et al, from Technical University in Munich, Germany found that some degree of IMT-SPECT uptake was present beyond the enhancement seen on T 1-weighted MR in all cases. IMT-SPECT uptake beyond the T2-weighted MR volume occurred in 30 of III patients (27%). On average, the IMT-SPECT volume is 30% greater than the T2-weighted MR volume (22) . The Institute J.
Bordet in Brussels, Belgium recently reported their initial experience in II patients using the combination of flourodeoxyglucose (FDG) and C-Il Methionine PET scans in conjunction with MR images for single fraction stereotactic radiosurgery treatment planning in recurrent (and presumably previously irradiated) malignant gliomas and brain metastases. In 6 of 11 patients (55%), the PET radiosurgical target volume was larger than the MR volume by 0.03 to 1.3cc (0.4-17.5%) (24) .
Although further data are needed, these studies demonstrate the limitations of conventional anatomic imaging for target volume definition in both conventional radiation therapy and stereotactic radiosurgery treatment planning and the potential application of MRSI, PET, and IMT-SPECT in more precise target delineation.
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Role for Biological imaging: Determining the Target Yolume
Challenges in the use of biological images in radiosurgery include i) multi-modality image registration, ii) knowledge of the information fidelity for the biological image modality in use (spatial resolution. spatial accuracy. sensitivity. specificity, and other measures of image quality), and iii) composition of the target volume from a set of individually delineated target volumes.
In general, multi-modality image registration is a solved problem (6, 25, 26) . However, while custom software tools have been developed at particular institutions, all commercial radiosurgery treatment planning systems cannot handle all types of (potential) image types or possibly a large number (ie, more than three) of image sets. Also, visualization tools, such as windowing and leveling may not perform in the accustomed fashion for biological images that have a variable range of voxel intensities or other unique character. While the DICOM and DICOM-RT image format standards (27) may assist with proper function for most software tools, new types of images will require verification of software performance.
Image information fidelity is an important aspect of image use. and has a great effect on the process of image interpretation. Whether qualitative or quantitative assessment is performed, image interpretation will yield diagnosis. classification of normal and target tissues, and/or evaluation of treatment. For instance, given a PET FDG image of a radiosurgical case, window and leveling can greatly vary the voxel intensities displayed, dramatically varying the volume of target that might be treated. The use of the specific uptake value (SUV) is important information to use for proper viewing of the PET image set. Thus, users of biological images must have experts able to interpret these images and should educate themselves on the character and limitations for the biological imaging mode.
Given image registration tools and an understanding of image fidelity, the clinical use of biological images is still challenged by the composition of the target volume. Current imaging techniques provide relatively simple binary targets that match well with high and low dose radiosurgery regions (ie, treat this target volume to high dose and do not treat this other volume at all, or treat it to low dose). Multi-modality biological imaging will cause the clinician to consider "margin" in a different manner. Figure I illustrates the problem of combining biological and anatomical images to yield a radiosurgical target volume. Image "quality" will vary with image modality and tumor type, giving different "truth" for one modality compared to another. Simple geometrical unions for a target volume, or exclusions for normal tissues, may suffice in some cases (for instance, for benign cases such as acoustic neuromas or meningiomas, or for some but not all low grade gliomas?) but should be proved first. Given initial results for biological neuro-oncologic imaging with MRSI (17. 18.20) . and PET (24) . where the biological image targets and MRI-enhancing volumes most likely are not congruent in size and shape. though one volume may at least contain the other. the close (ie. I mm) or zero margin radiosurgical treatment commonly used will be difficult to continue. or will continue with more irregularly shaped targets. Similarly. the radiation dose distribution used may be varied by choice across the target volume. based on interpreted biological content of the composite target. Thus. the binary volume of target and non-target is a soon-to-be questioned entity. whether for fractionated radiation treatment, radiosurgery. or surgery. In this regard. treatment in the future will be better matched to an individual patient's target biology because the "biological picture" will be better understood. What must be done is to search for the relevant biological image modalities that aid instead of hamper target designation. Modality choice will likely be more important in radiosurgical (or surgical) approaches compared to fractionated radiation treatment because of the one time opportunity for accurate treatment. Clearly, diagnostic radiologists. neurosurgeons, radiation oncologists, and physicists require education on the character of these new biological imaging modalities and on the necessity to evaluate their uses through clinical trials.
Summary
Stereotactic radiosurgery is used for highly focused radiation treatment of intracranial targets, using image-based approaches with CT and/or MR anatomical imaging. Biological imaging. at this time primarily provided by magnetic resonance spectroscopy imaging. positron emission tomography. and single photon emission computed tomography. will provide non-invasive. spatial assessment of target and normal tissue biology such as hypoxia. cell proliferation, and neurological function. Potential uses of biological imaging in stereotactic radiosurgery include target delineation. and normal tissue identification for avoidance. High certainty will be.required for image interpretation for biological imaging to be used effectively in single fraction radiosurgery. However. in general. biological imaging will provide a more complete "picture" of the patient's status to enable the most appropriate treatment.
Biological imaging and its evolving role in medicine is an exciting cross-disciplinary area of research that is a national priority and has great potential for impact on patient care. MRSI. in particular. may benefit patients with brain tumors who are treated with radiosurgery. A growing community of scientists and clinicians is addressing the acquisition. manipulation. and interpretation of biological images in the laboratory and clinical settings.
